Wave Life Sciences recently released its latest 10-Q report. The company is a clinical-stage biotechnology firm based in Singapore that develops RNA medicines through its PRISM platform. Its pipeline includes programs for obesity, alpha-1 antitrypsin deficiency, liver disease, Duchenne muscular dystrophy and Huntington’s disease, and it also has collaboration agreements with GlaxoSmithKline, Takeda Pharmaceutical, and Asuragen.
In Item 2, Management’s Discussion and Analysis, Wave said its business remains centered on RNA-targeting medicines, including RNA interference, RNA editing, antisense silencing and splicing. The company said PRISM combines multiple modalities, chemistry innovation and human genetics insights, and that its approach uses GalNAc conjugates or free uptake rather than lipid nanoparticles or viral delivery. Wave also said it is focusing on hepatic and metabolic programs, with WVE-007 for obesity, WVE-006 for alpha-1 antitrypsin deficiency and WVE-008 for PNPLA3 I148M liver disease as lead priorities.
Wave’s obesity program, WVE-007, is a GalNAc-conjugated siRNA designed to silence INHBE mRNA. The company said the target is aimed at fat loss while preserving muscle mass, and it cited preclinical data showing a single dose produced more than 70% Activin E reductions and weight loss comparable to daily semaglutide in diet-induced obese mice. In its INLIGHT Phase 1 trial, Wave reported interim data in December 2025 from 32 participants in the 240 mg cohort showing reductions in visceral fat, total fat mass and body weight, along with preservation of muscle, and said serum Activin E reductions were durable and dose-dependent. In March 2026, it said a single 240 mg dose produced placebo-adjusted reductions of 14% in visceral fat and 5% in total fat at six months, with lean mass up 2%, waist circumference down 3% and body weight down 1%. The company said the 240 mg, 400 mg and 600 mg cohorts were fully dosed, and it expects to start the Phase 2a portion in the second quarter of 2026.
For WVE-006, Wave said the program uses GalNAc-conjugated AIMers to correct a single base in mutant SERPINA1 mRNA for alpha-1 antitrypsin deficiency. The company said the program is first-in-class in AATD and the most advanced oligonucleotide clinical program using an endogenous enzyme for RNA editing. In September 2025, Wave reported data from the RestorAATion-2 study, including a single 200 mg dose and multidose cohort of eight patients each, plus a 400 mg single-dose cohort of eight patients. It said one patient had total AAT of 20.6 µM and M-AAT of 10.3 µM during an acute phase response, while the 200 mg multidose cohort showed total AAT of 11.9 µM, M-AAT of 7.2 µM and mutant Z-AAT down 60.3% from baseline.
Wave said WVE-008 is a GalNAc-conjugated RNA editing oligonucleotide for PNPLA3 I148M liver disease, while WVE-N531 is an exon 53 splicing oligonucleotide for Duchenne muscular dystrophy and WVE-003 is an allele-selective oligonucleotide for Huntington’s disease. It said the pipeline also includes several preclinical programs across hepatic and extra-hepatic tissues. The market has reacted to these announcements by moving the company's shares -1.78% to a price of $7.18. Check out the company's full 10-Q submission here.
